FDA to approve new drug for Parkinson’s disease

Health regulators are expected to approve the first prescription from a company developing a new type of drug to treat Parkinson’s, a condition that afflicts at least 1 in 4 Americans.

The U.S. Food and Drug Administration on Wednesday gave preliminary approval to Rizvi Biotechnologies, a New York-based company, for a drug that works by targeting the genetic material of certain cells in the body.

The approval will likely come in the next few weeks, as FDA officials prepare to submit the final draft of the agency’s final rule to Congress on Wednesday, according to a statement from the agency.

Rizvi has not yet been approved by the Food and Drugs Administration.

The drug, called N-acetylcysteine (NAC), is a type of vitamin that may help people with the degenerative brain disease.

The FDA approved the drug in January, and the company said it expects to receive approval in the coming months.

The company is not the first to make a drug targeting the disease.

Last year, researchers at Massachusetts General Hospital, Boston Children’s Hospital and Tufts Medical Center announced that they had created a drug to protect neurons from being damaged by the disease called BDNF, or “brain-derived neurotrophic factor.”

But this is the first time the FDA has approved a drug for the condition, which affects about 1 in 2,000 Americans.

That is about a 10 percent increase in the number of people with Parkinson’s.

The new drug would be similar to an existing drug, which is used to treat people with Huntington’s disease and Huntington’s-associated memory loss.

That drug, however, does not target the brain, according a statement.

“It is an exciting time for patients and scientists alike,” said James C. Schumacher, chairman of the FDA’s Center for Drug Evaluation and Research.

“With this approval, the FDA will begin a new phase in our nation’s efforts to develop novel, effective treatments for Parkinson.”

The company expects the drug to be available in the first quarter of 2020.

Rozvi will also likely get approval for another treatment called Zeta, which was approved in late 2015 for treating Alzheimer’s disease.

Zeta works by preventing the body from degrading the neurons in the brain.

Rizvias drug is similar to Zeta.

The FDA previously approved another new drug, known as BSNF-17, to treat Huntington’s in April.